Clinical trials: Inadequate Response
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Inflammation, Rheumatoid Arthritis
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This trial is conducted in Europe. The aim of the trial is to investigate the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis (RA) and an inadequate response to…
- Trial name
- NCT02097264
- Testing
- NNC0109-0012, Adalimumab
- Sponsor
- Novo Nordisk A/S
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Rheumatoid Arthritis
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment.
- Trial name
- NCT02006706
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 3 sites in Serbia
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
- Trial name
- NCT02047604
- Testing
- SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Bausch Health Americas, Inc.
Rheumatoid Arthritis
A Study in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to…
- Trial name
- RA-BEAM (NCT01710358)
- Testing
- Adalimumab, Baricitinib, Methotrexate
- Where
- 213 sites in United States, Argentina and 26 more
- Volunteers
- 1,307 people
- Sponsor
- Eli Lilly and Company
Acute Decompensated Heart Failure
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05876078
- Testing
- Doraya catheter
- Where
- 10 sites in Germany, Italy and 3 more
- Volunteers
- 25 people
- Sponsor
- Revamp Medical Ltd.
Primary Biliary Cirrhosis (PBC)
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).
- Trial name
- NCT02609048
- Testing
- Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of CKD-506 on signs and symptoms of RA in subjects with moderate-to-severe RA who are inadequate responders to methotrexate.
- Trial name
- NCT04204603
- Testing
- CKD-506
- Where
- 38 sites in Czechia, Georgia and 3 more
- Volunteers
- 122 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to…
- Trial name
- SELECT-COMPARE (NCT02629159)
- Testing
- Adalimumab, Upadacitinib
- Where
- 370 sites in United States, Argentina and 42 more
- Volunteers
- 1,629 people
- Sponsor
- AbbVie
Gout
Combining Lesinurad With Allopurinol in Inadequate Responders
This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to…
- Trial name
- CLEAR 1 (NCT01510158)
- Testing
- Lesinurad, Allopurinol
- Where
- 165 sites in United States
- Volunteers
- 607 people
- Sponsor
- Ardea Biosciences, Inc.
Rheumatoid Arthritis
Abatacept Post-marketing Clinical Study in Japan
The purpose of this study is to compare the clinical efficacy including joint damage progression and safety of Abatacept plus Methotrexate (MTX) to placebo plus MTX.
- Trial name
- NCT01758198
- Testing
- Abatacept, Methotrexate
- Where
- 74 sites in Japan
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult…
- Trial name
- RESOLVE (NCT05604885)
- Testing
- AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg
- Where
- Moldova
- Volunteers
- 125 people
- Sponsor
- SynAct Pharma Aps
Myocardial Ischemia, Blood Coagulation Disorders
"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
Aims and Hypotheses: This randomised placebo controlled study will test the hypothesis that Recombinant Activated Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional therapy in complex cardiac…
- Conditions
- Myocardial Ischemia, Blood Coagulation Disorders, Coronary Artery Disease, Heart Valve Diseases
- Trial name
- NCT00214656
- Testing
- Recombinant Activated Factor VII
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Austin Health
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Rheumatoid Arthritis
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
This Phase IIIb, open-label, single-arm study will evaluate the safety, efficacy, and tolerability of SC tocilizumab (RoActemra/Actemra) in monotherapy or in combination with methotrexate or other non-biologic DMARDs in…
- Trial name
- NCT02046616
- Testing
- Tocilizumab, Methotrexate, Non-Biologic DMARDs
- Where
- 27 sites in Denmark, Finland and 2 more
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy.
- Trial name
- SATELITE (NCT04871191)
- Testing
- Rituximab, Tocilizumab, Tofacitinib
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Human Immunodeficiency Virus
Improving Prognosis in HIV Infection
The primary objective of this study is to assess the safety of probiotics in cART-treated immunologic non-responder (INR) patients with chronic HIV infection.
- Trial name
- NCT02640625
- Testing
- Probiotic compound
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital